Literature DB >> 27166830

Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Domenico Plantone1, Floriana De Angelis2, Anisha Doshi2, Jeremy Chataway2.   

Abstract

Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27166830     DOI： 10.1007/s40263-016-0340-9

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  147 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  Neurofilaments as biomarkers in multiple sclerosis.

Authors:  Charlotte E Teunissen; Michael Khalil
Journal:  Mult Scler       Date:  2012-04-04       Impact factor: 6.312

3.  Diffusion tensor MR imaging of the human brain.

Authors:  C Pierpaoli; P Jezzard; P J Basser; A Barnett; G Di Chiro
Journal:  Radiology       Date:  1996-12       Impact factor: 11.105

Review 4.  The use of optical coherence tomography in neurology.

Authors:  Cédric Lamirel; Nancy Newman; Valéerie Biousse
Journal:  Rev Neurol Dis       Date:  2009

5.  Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.

Authors:  Roberto Madeddu; Cristiano Farace; Paola Tolu; Giuliana Solinas; Yolande Asara; Maria Alessandra Sotgiu; Lucia Gemma Delogu; Jose Carlos Prados; Stefano Sotgiu; Andrea Montella
Journal:  Neurol Sci       Date:  2012-02-24       Impact factor: 3.307

6.  The natural history of secondary progressive multiple sclerosis.

Authors:  Marcus Koch; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

Review 7.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 8.  Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors.

Authors:  Tatiana Koudriavtseva; Rosaria Renna; Domenico Plantone; Caterina Mainero
Journal:  Front Neurol       Date:  2015-03-24       Impact factor: 4.003

9.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501
View more
  15 in total

Review 1.  Riboflavin in Neurological Diseases: A Narrative Review.

Authors:  Domenico Plantone; Matteo Pardini; Giuseppe Rinaldi
Journal:  Clin Drug Investig       Date:  2021-04-22       Impact factor: 2.859

Review 2.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

3.  Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.

Authors:  Alex Lewin; Shea Hamilton; Aviva Witkover; Paul Langford; Richard Nicholas; Jeremy Chataway; Charles R M Bangham
Journal:  Wellcome Open Res       Date:  2016-11-15

4.  Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Authors:  Bruno Brochet; Mathilde S A Deloire; Paul Perez; Timothé Loock; Louise Baschet; Marc Debouverie; Sophie Pittion; Jean-Christophe Ouallet; Pierre Clavelou; Jérôme de Sèze; Nicolas Collongues; Patrick Vermersch; Hélène Zéphir; Giovanni Castelnovo; Pierre Labauge; Christine Lebrun; Mikael Cohen; Aurélie Ruet
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

5.  Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.

Authors:  Marcello Moccia; Raffaele Palladino; Roberta Lanzillo; Antonio Carotenuto; Cinzia Valeria Russo; Maria Triassi; Vincenzo Brescia Morra
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

Review 6.  Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.

Authors:  Aaron E Miller
Journal:  Ther Adv Neurol Disord       Date:  2017-09-13       Impact factor: 6.570

7.  Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation.

Authors:  Alice Valentin-Torres; Carine Savarin; Joslyn Barnett; Cornelia C Bergmann
Journal:  J Neuroinflammation       Date:  2018-04-24       Impact factor: 8.322

Review 8.  The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue.

Authors:  Trevor O Kirby; Javier Ochoa-Repáraz
Journal:  Med Sci (Basel)       Date:  2018-08-24

9.  A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application.

Authors:  Tianrong Yeo; Megan Sealey; Yifan Zhou; Luisa Saldana; Samantha Loveless; Timothy D W Claridge; Neil Robertson; Gabriele DeLuca; Jacqueline Palace; Daniel C Anthony; Fay Probert
Journal:  Sci Rep       Date:  2020-07-24       Impact factor: 4.996

10.  Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Authors:  Peter Connick; Floriana De Angelis; Richard A Parker; Domenico Plantone; Anisha Doshi; Nevin John; Jonathan Stutters; David MacManus; Ferran Prados Carrasco; Frederik Barkhof; Sebastien Ourselin; Marie Braisher; Moira Ross; Gina Cranswick; Sue H Pavitt; Gavin Giovannoni; Claudia Angela Gandini Wheeler-Kingshott; Clive Hawkins; Basil Sharrack; Roger Bastow; Christopher J Weir; Nigel Stallard; Siddharthan Chandran; Jeremy Chataway
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.